Estados financieros detallados de OmniAb, Inc. (OABI): cuenta de resultados, balance general y flujo de caja. Sigue la evolución de márgenes, deuda, liquidez y rentabilidad año a año con hasta 20 años de histórico.
Resumen del Análisis
OmniAb, Inc. registró ingresos de $18.7M en el último ejercicio fiscal, con un CAGR de 5 años del -4.3%.
Márgenes de los últimos 12 meses: margen bruto 50.5%, margen operativo -125.8%, margen neto -115.2%.
Al precio actual de $4.35, OABI presenta beneficios negativos (P/E no significativo) y un ROE del -16.59%. La capitalización bursátil es de $631M.
Cuenta de Resultados (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Ingresos | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | $18.7M |
| Coste de Ventas | 0 | 0 | 0 | 0 | 0 | 0 | $22.1M |
| Beneficio Bruto | $18.3M | $23.3M | $34.7M | $59.1M | $34.2M | $26.4M | -$3.4M |
| I+D | $13.2M | $24.8M | $39.2M | $48.4M | $56.5M | $55.1M | $47.8M |
| Generales y Administrativos | $8.7M | $10.2M | $16.9M | $24.9M | $33.3M | $30.7M | $29.2M |
| Gastos Operativos | $31.3M | $48.9M | $70.4M | $85.7M | $103.6M | $100.9M | $68.1M |
| Beneficio Operativo | -$13.0M | -$25.6M | -$35.6M | -$26.6M | -$69.4M | -$74.5M | -$71.5M |
| EBITDA | -$3.3M | -$10.9M | -$18.1M | -$7.8M | -$44.9M | -$47.8M | -$44.5M |
| Gastos por Intereses | 0 | $5000 | $7000 | 0 | 0 | 0 | 0 |
| Beneficio Antes de Impuestos | -$13.0M | -$23.7M | -$34.4M | -$26.1M | -$64.4M | -$71.4M | -$66.3M |
| Impuestos | $562000 | -$6.2M | -$7.3M | -$3.7M | -$13.7M | -$9.4M | -$1.5M |
| Beneficio Neto | -$13.6M | -$17.6M | -$27.0M | -$22.3M | -$50.6M | -$62.0M | -$64.8M |
| BPA | $-0.12 | $-0.15 | $-0.24 | $-0.26 | $-0.51 | $-0.61 | $-0.57 |
| BPA Diluido | $-0.12 | $-0.15 | $-0.24 | $-0.26 | $-0.51 | $-0.61 | $-0.57 |
| Acciones en Circulación (Diluidas) | $114.8M | $114.8M | $114.8M | $85.3M | $99.7M | $102.4M | $113.6M |
Balance (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Caja y Equivalentes | 0 | 0 | 0 | $33.4M | $16.4M | $27.6M | $25.5M |
| Inversiones a Corto | 0 | 0 | 0 | $54.9M | $70.6M | $31.8M | $28.5M |
| Cuentas por Cobrar | $7.8M | $15.9M | $21.1M | $30.3M | $3.8M | $5.3M | $7.4M |
| Inventario | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Activos Corrientes | $7.8M | $16.6M | $22.5M | $125.0M | $94.9M | $68.1M | $65.3M |
| Inmovilizado Material | $4.3M | $6.0M | $20.1M | $41.5M | $38.1M | $33.3M | $25.0M |
| Fondo de Comercio | $77.1M | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M | $84.0M |
| Activos Intangibles | $173.0M | $186.6M | $176.3M | $167.2M | $155.5M | $138.1M | $125.1M |
| Activos Totales | $262.3M | $295.4M | $304.5M | $421.2M | $375.2M | $325.6M | $300.9M |
| Cuentas por Pagar | $806000 | $469000 | $2.9M | $3.0M | $4.4M | $2.3M | $1.9M |
| Deuda a Corto | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Corrientes | $6.1M | $14.3M | $20.6M | $26.0M | $23.1M | $15.1M | $16.3M |
| Deuda a Largo | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pasivos Totales | $44.1M | $59.8M | $70.2M | $79.8M | $60.6M | $37.9M | $33.9M |
| Reservas | 0 | 0 | 0 | $11.3M | -$39.4M | -$101.4M | -$166.2M |
| Patrimonio Neto | $218.2M | $235.5M | $234.3M | $341.4M | $314.6M | $287.6M | $267.0M |
| Deuda Total | $2.6M | $2.6M | $13.8M | $25.8M | $25.6M | $23.2M | $20.3M |
| Deuda Neta | $2.6M | $2.6M | $13.8M | -$62.5M | -$61.4M | -$36.3M | -$33.7M |
| Capital Circulante | $1.7M | $2.4M | $2.0M | $98.9M | $71.8M | $53.0M | $49.1M |
Flujo de Caja (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Beneficio Neto | -$13.6M | -$17.6M | -$27.0M | -$22.3M | -$50.6M | -$62.0M | -$64.8M |
| Amortizaciones | $10.9M | $13.1M | $16.3M | $18.2M | $19.5M | $23.6M | $21.8M |
| Compensación en Acciones | $6.7M | $9.2M | $15.1M | $18.3M | $24.8M | $21.5M | $15.8M |
| Cambio en Capital Circulante | -$8.9M | $4.7M | -$2.6M | -$10.8M | $24.9M | -$10.2M | -$5.0M |
| Flujo de Caja Operativo | -$5.2M | $3.6M | -$5.7M | -$3.6M | $2.3M | -$39.7M | -$36.5M |
| Inversiones (CapEx) | -$255000 | -$1.8M | -$4.1M | -$17.2M | -$1.6M | -$1.9M | -$565000 |
| Adquisiciones | -$11.8M | -$27.1M | 0 | 0 | 0 | 0 | 0 |
| Recompra de Acciones | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividendos Pagados | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Flujo de Caja Libre | -$5.5M | $1.9M | -$9.7M | -$20.8M | $703000 | -$41.5M | -$37.0M |
Crecimiento y Márgenes (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Crecimiento Ingresos (anual) | +27.0% | +49.3% | +70.0% | -42.2% | -22.8% | -29.3% | |
| Crecimiento Beneficio Neto (anual) | -29.2% | -54.0% | +17.4% | -126.6% | -22.5% | -4.4% | |
| Crecimiento BPA (anual) | -25.0% | -60.0% | -8.3% | -96.2% | -19.6% | +6.6% | |
| Cambio en Acciones (anual) | +0.0% | +0.0% | -25.7% | +16.8% | +2.7% | +11.0% | |
| Crecimiento FCF (anual) | +134.2% | -622.1% | -113.0% | +103.4% | -6008.8% | +10.9% | |
| Margen Bruto | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| Margen Operativo | -71.1% | -110.1% | -102.5% | -45.1% | -203.2% | -282.3% | -383.1% |
| Margen EBITDA | -17.8% | -47.0% | -52.1% | -13.2% | -131.3% | -181.2% | -238.6% |
| Margen Neto | -74.2% | -75.5% | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
| Margen FCF | -29.8% | 8.0% | -28.0% | -35.1% | 2.1% | -157.4% | -198.3% |
| Tasa Impositiva Efectiva | -4.3% | 26.0% | 21.3% | 14.3% | 21.4% | 13.1% | 2.3% |
Datos por Acción (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| FCF por Acción | $-0.05 | $0.02 | $-0.08 | $-0.24 | $0.01 | $-0.41 | $-0.33 |
| Dividendo por Acción | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Acciones en Circulación (Básicas) | $114.8M | $114.8M | $114.8M | $85.3M | $99.7M | $102.4M | $113.6M |
Qué mirar en Biotech
La mayoría de biotechs pequeñas pierden dinero. Analizarlas con P/E no tiene sentido — mira caja y pipeline.
- Cash Runway — Meses de caja al ritmo de gasto actual. <18 meses = riesgo de dilución urgente
- Cash burn anual — Ritmo al que queman caja operativa. Comparar con posición de caja para proyectar runway
- Total Debt — Biotech sin ingresos + deuda = receta para bancarrota
- I+D / Capitalización — Cuánto invierten en pipeline vs lo que vale la empresa — indicador de intensidad investigadora
- Market cap / Cash — Si cotiza cerca de su caja, el mercado le da ~0 valor al pipeline — puede ser oportunidad o trampa
Rentabilidad
| Rentabilidad sobre capital | -16.59% |
| Rentabilidad sobre capital invertido | -17.24% |
| Rentabilidad sobre activos | -15.25% |
| Margen bruto | 50.53% |
| Margen operativo | -125.79% |
| Margen neto | -115.18% |
Salud financiera
| Deuda / Patrimonio | 0.07 |
| Ratio corriente | 4.80 |
| Piotroski F-Score | 1 |
| Altman Z-Score | 2.42 |
Ratios Clave (10 años)
| Año | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| P/E | -81.33 | -65.07 | -41.67 | -13.85 | -12.10 | -5.80 | -3.25 |
| P/VC | 5.14 | 4.76 | 4.90 | 0.90 | 1.96 | 1.26 | 0.79 |
| P/V | 61.18 | 48.16 | 33.04 | 5.20 | 18.00 | 13.73 | 11.26 |
| Margen Bruto | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -18.2% |
| Margen Operativo | -71.1% | -110.1% | -102.5% | -45.1% | -203.2% | -282.3% | -383.1% |
| Margen Neto | -74.2% | -75.5% | -77.8% | -37.8% | -148.2% | -235.1% | -347.0% |
Empresas relacionadas: ARMP · CCCC · CDXS · IMDX · IPHA · IVVD · MIST
Explorar sector: Healthcare · Biotechnology
Más secciones de OABI: Resumen · Valoración · Estadísticas · Estimaciones · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones